Exploiting bacterial outer membrane vesicles as a cross-protective vaccine candidate against avian pathogenic Escherichia coli (APEC).
BACKGROUND
The well-known fact that avian pathogenic Escherichia coli (APEC) is harder to prevent due to its numerous serogroups has promoted the development of biological immunostimulatory materials as new vaccine candidates in poultry farms. Bacterial outer membrane vesicles (OMVs), known as spherical nanovesicles enriched with various immunostimulants, are naturally secreted by Gram-negative bacteria, and have gained much attention for developing effective vaccine candidates. Recent report has demonstrated that OMVs of APEC O78 can induce protective immunity in chickens. Here, a novel multi-serogroup OMVs (MOMVs) vaccine was developed to achieve cross-protection against APEC infection in broiler chickens.


RESULTS
In this study, OMVs produced by three APEC strains were isolated, purified and prepared into MOMVs by mixing these three OMVs. By using SDS-PAGE and LC-MS/MS, 159 proteins were identified in MOMVs and the subcellular location and biological functions of 20 most abundant proteins were analyzed. The immunogenicity of MOMVs was evaluated, and the results showed that MOMVs could elicit innate immune responses, including internalization by chicken macrophage and production of immunomodulatory cytokines. Vaccination with MOMVs induced specific broad-spectrum antibodies as well as Th1 and Th17 immune responses. The animal experiment has confirmed that immunization with an appropriate dose of MOMVs could not cause any adverse effect and was able to reduce bacteria loads and pro-inflammatory cytokines production, thus providing effective cross-protection against lethal infections induced by multi-serogroup APEC strains in chickens. Further experiments indicated that, although vesicular proteins were able to induce stronger protective efficiency than lipopolysaccharide, both vesicular proteins and lipopolysaccharide are crucial in MOMVs-mediated protection.


CONCLUSIONS
The multi-serogroup nanovesicles produced by APEC strains will open up a new way for the development of next generation vaccines with low toxicity and broad protection in the treatment and control of APEC infection.
['Hu|Rujiu|R|http://orcid.org/0000-0002-6090-0209', 'Li|Jing|J|', 'Zhao|Yuezhen|Y|', 'Lin|Hua|H|', 'Liang|Liu|L|', 'Wang|Mimi|M|', 'Liu|Haojing|H|', 'Min|Yuna|Y|', 'Gao|Yupeng|Y|', 'Yang|Mingming|M|']
D000818:Animals D000907:Antibodies, Bacterial D000942:Antigens, Bacterial D000080943:Bacterial Outer Membrane D001425:Bacterial Outer Membrane Proteins D002645:Chickens D056738:Cross Protection D016207:Cytokines D004926:Escherichia coli D022361:Escherichia coli Vaccines D008264:Macrophages D011201:Poultry Diseases
Outer membrane vesicles Cross-protection Vaccine Multi-serogroup Immune response Avian pathogenic E. coli (APEC)